# Stuart A Weinzimer

List of Publications by Year
in descending order



| 63 | 8,377 | 186265 28 | 118850 62 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 67 | 67 | 67 | 5811 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603. | 8.6 | 2,101 |
| 2 | International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017, 40, 1631-1640. | 8.6 | 1,376 |
| 3 | Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal of Medicine, 2008, 359, 1464-1476. | 27.0 | 1,369 |
| 4 | Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 1407. | 7.4 | 515 |
| 5 | Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Diabetes Care, 2008, 31, 934-939. | 8.6 | 510 |
| 6 | Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care, 2018, 41, 2026-2044. | 8.6 | 288 |
| 7 | Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 2016, 39, 1175-1179. | 8.6 | 195 |
| 8 | Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care, 2018, 41, 2155-2161. | 8.6 | 184 |
| 9 | Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report. Pediatrics, 2004, 114, 1601-1605. | 2.1 | 152 |
| 10 | Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine, 2020, 26, 1380-1384. | 30.7 | 127 |
| 11 | Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes. Diabetes Care, 2012, 35, 1994-1999. | 8.6 | 124 |
| 12 | Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia. Diabetes, 2015, 64, 1770-1779. | 0.6 | 107 |
| 13 | Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care, 2018, 41, 789-796. | 8.6 | 101 |
| 14 | Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Diabetes Educator, 2017, 43, 223-232. | 2.5 | 78 |
| 15 | Impact of Early Diabetic Ketoacidosis on the Developing Brain. Diabetes Care, 2019, 42, 443-449. | 8.6 | 77 |
| 16 | Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care, 2016, 39, 1127-1134. | 8.6 | 75 |
| 17 | FreeStyle Navigator Continuous Glucose Monitoring System Use in Children With Type 1 Diabetes Using Glargine-Based Multiple Daily Dose Regimens. Diabetes Care, 2008, 31, 525-527. | 8.6 | 69 |
| 18 | Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes, 2016, 65, 476-485. | 0.6 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes. Journal of the Endocrine Society, 2017, 1, 1461-1476. | 0.2 | 53 |
| 20 | A Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart Versus Insulin Lispro in Children and Adolescents With Type 1 Diabetes. Diabetes Care, 2008, 31, 210-215. | 8.6 | 51 |
| 21 | Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes, 2017, 18, 348-355. | 2.9 | 46 |
| 22 | Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technology and Therapeutics, 2017, 19, 288-292. | 4.4 | 46 |
| 23 | Schooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings. Pediatric Diabetes, 2018, 19, 92-97. | 2.9 | 42 |
| 24 | Evolution of Abnormal Plasma Glucagon Responses to Mixed-Meal Feedings in Youth With Type 1 Diabetes During the First 2 Years After Diagnosis. Diabetes Care, 2014, 37, 1741-1744. | 8.6 | 38 |
| 25 | Emerging evidence for the use of insulin pump therapy in infants, toddlers, and preschool-aged children with type 1 diabetes. Pediatric Diabetes, 2006, 7, 15-19. | 2.9 | 37 |
| 26 | Predictors of Time-in-Range (70â€“180â€‰mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technology and Therapeutics, 2021, 23, 475-481. | 4.4 | 36 |
| 27 | Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology and Therapeutics, 2016, 18, 794-799. | 4.4 | 32 |
| 28 | Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology and Therapeutics, 2018, 20, 648-653. | 4.4 | 29 |
| 29 | Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. Diabetes Technology and Therapeutics, 2021, 23, 857-861. | 4.4 | 28 |
| 30 | Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care, 2021, 44, 473-478. | 8.6 | 28 |
| 31 | Analysis of Continuous Glucose Monitoring Data from Non-Diabetic and Diabetic Children: A Tale of Two Algorithms. Diabetes Technology and Therapeutics, 2003, 5, 375-380. | 4.4 | 27 |
| 32 | Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes. Diabetes, 2017, 66, 754-762. | 0.6 | 25 |
| 33 | Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology and Therapeutics, 2017, 19, 618-622. | 4.4 | 24 |
| 34 | Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes. Human Brain Mapping, 2016, 37, 4034-4046. | 3.6 | 23 |
| 35 | Longitudinal assessment of hippocampus structure in children with type 1 diabetes. Pediatric Diabetes, 2018, 19, 1116-1123. | 2.9 | 23 |
| 36 | The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. Pediatric Diabetes, 2018, 19, 14-17. | 2.9 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Sensor-augmented pump therapy in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 118-122. | 2.3 | 20 |
| 38 | Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1088-1094. | 3.6 | 19 |
| 39 | Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet Journal of Rare Diseases, 2022, 17, 61. | 2.7 | 19 |
| 40 | Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies. Clinical Pediatrics, 2005, 44, 393-403. | 0.8 | 17 |
| 41 | Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory. Diabetes, 2020, 69, 1770-1778. | 0.6 | 15 |
| 42 | Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics of North America, 2005, 52, 1677-1688. | 1.8 | 14 |
| 43 | Closed-loop artificial pancreas. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 88-92. | 2.3 | 12 |
| 44 | Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care, 2020, 43, 2146-2152. | 8.6 | 12 |
| 45 | Establishing a Global Standard for Wearable Devices in Sport and Exercise Medicine: Perspectives from Academic and Industry Stakeholders. Sports Medicine, 2021, 51, 2237-2250. | 6.5 | 12 |
| 46 | Technology Utilization in Black Adolescents with Type 1 Diabetes: Exploring the Decision-Making Process. Diabetes Technology and Therapeutics, 2022, 24, 249-257. | 4.4 | 12 |
| 47 | Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatric Diabetes, 2016, 17, 237-243. | 2.9 | 11 |
| 48 | Continuous glucose monitoring in type 1 diabetes. Current Diabetes Reports, 2004, 4, 95-100. | 4.2 | 10 |
| 49 | Life With Type 1 Diabetes. The Diabetes Educator, 2016, 42, 408-417. | 2.5 | 9 |
| 50 | Feasibility and safety of a group physical activity program for youth with type 1 diabetes. Pediatric Diabetes, 2019, 20, 450-459. | 2.9 | 9 |
| 51 | Evaluation of Web-Based and In-Person Methods to Recruit Adults With Type 1 Diabetes for a Mobile Exercise Intervention: Prospective Observational Study. JMIR Diabetes, 2021, 6, e28309. | 1.9 | 9 |
| 52 | Bayesian structural time series for biomedical sensor data: A flexible modeling framework for evaluating interventions. PLoS Computational Biology, 2021, 17, e1009303. | 3.2 | 8 |
| 53 | Youth and parent preferences for an ideal <scp>AP</scp> system: It is all about reducing burden. Pediatric Diabetes, 2021, 22, 1063-1070. | 2.9 | 8 |
| 54 | Analysis: How to Inspect When She's Expecting: Use of Continuous Glucose Monitoring in Diabetes During Pregnancy. Diabetes Technology and Therapeutics, 2005, 7, 707-709. | 4.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Effects of Frequency of Sensor-Augmented Pump Use on HbA1cand C-Peptide Levels in the First Year of Type 1 Diabetes. Diabetes Care, 2016, 39, e61-e62. | 8.6 | 5 |
| 56 | Fellows as Medical Educators: Implementation and Evaluation of a Curriculum to Improve Pediatric Fellow Teaching Skills. Academic Pediatrics, 2020, 20, 140-142. | 2.0 | 4 |
| 57 | Practical Implementation of Diabetes Technology: Realâ€World Use. Diabetes Technology and Therapeutics, 2020, 22, S-119-S-129. | 4.4 | 3 |
| 58 | Innovative features and functionalities of an artificial pancreas system: What do youth and parents want?. Diabetic Medicine, 2021, 38, e14492. | 2.3 | 3 |
| 59 | Practical Diabetes Technology: Overcoming Barriers in the Real World. Diabetes Technology and Therapeutics, 2021, 23, S-159-S-168. | 4.4 | 3 |
| 60 | Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 461-472. | 0.9 | 3 |
| 61 | Analysis: High-Tech Diabetes Technology and the Myth of Clinical â€œPlug and Playâ€. Journal of Diabetes Science and Technology, 2010, 4, 1465-1467. | 2.2 | 2 |
| 62 | An Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 Diabetes. SAGE Open Nursing, 2018, 4, 237796081880474. | 1.2 | 2 |
| 63 | Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Journal of Diabetes Science and Technology, 2019, 13, 1123-1128. | 2.2 | 2 |